Attendee search 

Provectus Biopharmaceuticals, Inc., specializes in developing oncology and dermatology therapies. PV-10, its novel investigational drug for cancer, is designed for injection into solid tumors (intralesional administration), thereby reducing potential for systemic side effects. Its oncology focus in on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH-10, its topical investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dematitis. Provectus has completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH10 as a topical treatment for atopic dermatitis and psoriasis.

Drooms is the leading provider of data rooms in Europe. The specialized software facilitates highly secure access to confidential documents, as well as the ability to exchange them safely with third parties beyond company firewalls. Drooms allows for the transparent, efficient and secure management of confidential business processes such as commercial real estate sales, mergers and acquisitions, NPL transactions and board communications. Drooms’ clients include the world's leading real estate companies, consulting and law firms and corporations such as METRO GROUP, Evonik, Morgan Stanley, JLL, JP Morgan, CBRE, Rewe and UBS.

Drooms is the leading provider of data rooms in Europe. The specialized software facilitates highly secure access to confidential documents, as well as the ability to exchange them safely with third parties beyond company firewalls. Drooms allows for the transparent, efficient and secure management of confidential business processes such as commercial real estate sales, mergers and acquisitions, NPL transactions and board communications. Drooms’ clients include the world's leading real estate companies, consulting and law firms and corporations such as METRO GROUP, Evonik, Morgan Stanley, JLL, JP Morgan, CBRE, Rewe and UBS.